Sep 2026· Frontiers in Drug Discovery· 1 citation· 175 references
TL;DR
Overall, continued advances in translational vaccinology, computational vaccine design, and global preparedness may accelerate the development of NiV vaccines.
Abstract
Nipah virus (NiV) is a highly pathogenic zoonotic member of the genus
Henipavirus
. Due to its high fatality rate and increasing evidence of human-to-human transmission, it remains a major global health concern. Since its first emergence during the Malaysian outbreak, NiV has caused repeated outbreaks across South and Southeast Asia, particularly in Bangladesh and India. The absence of licensed vaccines or specific antiviral therapies has intensified the need for global efforts toward vaccine development and outbreak preparedness. This review aims to provide a comprehensive overview of the current status of NiV vaccine research, with emphasis on recent advances in vaccine platforms in preclinical and clinical trials. Relevant literature related to NiV epidemiology, viral pathogenesis, immunobiology, and vaccine development was comprehensively reviewed to summarize current knowledge and recent advances in vaccine development. Major vaccine approaches critically evaluated for their immunogenicity and protective response in this study include recombinant soluble glycoprotein subunit vaccines, viral-vectored vaccines, mRNA-based vaccines, DNA vaccines, virus-like particles, and nanoparticle-based systems. Recent advances in immunoinformatic-guided multi-epitope vaccine design and rapid-response vaccine manufacturing strategies were also assessed in the context of emerging pandemic preparedness initiatives such as Coalition for Epidemic Preparedness Innovations (CEPI) “100 Days Mission”. Current evidence indicates that several NiV vaccine candidates, like subunit, viral-vectored, and mRNA-based platforms, have progressed from experimental to early-phase clinical evaluation. However, the absence of validated immune correlates of protection, limited outbreak predictability, difficulties in conventional efficacy trials, and antigenic variability pose major challenges in outbreak-prone regions. Overall, continued advances in translational vaccinology, computational vaccine design, and global preparedness may accelerate the development of NiV vaccines.
Simple Summary This review elucidates the antigenic architecture of Bluetongue virus (BTV) and the ensuing immune responses. It critically evaluates the advantages and disadvantages of conventional vaccines relative to emerging vaccine platforms. Furthermore, it underscores the imperative for future research to develop...
Xin-Yi Li, Zheng-Hao Ye, Ni-Jing Lei et al.· Veterinary Sciences· 0 citations
Background Avian influenza viruses (AIVs), particularly highly pathogenic H5 and H7 viruses, pose major threats to poultry production, food security, international trade, and public health. Vaccination is an important component of AIV control; however, antigenic evolution, incomplete reduction of viral shedding, and ch...
M. Nazari, M. Mehrazar· Veterinary and Animal Scienc...· 0 citations
The human monoclonal antibody MR191N provides complete post-exposure protection in non-human primates and necessitates adaptive trial designs, expanded diagnostic models, and synergistic combination therapies to address MVD.
V. Kandi, F. Branda, Mohammed Alissa et al.· Expert Review of Anti-Infect...· 0 citations
Haemorrhagic septicemia (HS), caused by Pasteurella multocida serotypes B:2 and E:2, remains a major infectious disease of cattle and buffalo in endemic regions of Asia and Africa and has increasingly been recognized as a threat to susceptible wildlife. Despite decades of vaccination, recurrent outbreaks continue, high...
R. Raj, Ashwani Kumar Sharma· Discover Animals· 0 citations
Malaria remains a major global health burden, with Plasmodium falciparum responsible for the majority of severe disease and mortality, particularly in sub-Saharan Africa, as consistently reported by the World Health Organization. Although recent vaccine approvals marked significant progress, currently deployed protein-...
Mutebi Mark· IDOSR Journal of Scientific...· 0 citations
The aim of this review is to summarize the evidence on contemporary candidate vaccines against monkeypox developed using different approaches, and addresses both classical live attenuated vaccinia virus-based vaccines, previously approved for prevention of monkeypox, and vaccines being developed using recombinant techn...
A. A. Sulgin, A. Ilyichev, M. Azaev et al.· Journal of microbiology, epi...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.